This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with subsequent escalation has been challenged by new data suggesting that MS patients derive greater benefit when therapy is initiated with high-efficacy treatment agents (HETA). Several recent studies compared treatment efficacy and safety of early administration of HETA versus LETA. The results of randomized, double blind, phase III studies with LETA as a control arm and population-based larger and longer studies using propensity scoring, marginal structural modeling and weighted cumulative exposure analysis support the benefit of early treatment with HETA. Patients initiating their treatment with HETA, regardless of prognostic factors and MRI burden at baseline, showed significantly lower annualized relapse rate (ARR) and reduced disability progression in follow-up periods of up to 10-15 years. Moreover, the safety profile of recently approved HETA ameliorates concerns about off-target effects associated with a number of earlier high-efficacy drugs. Patient perception has also changed with an increasing preference for medication profiles that both improve symptoms and prevent disease progression. Accumulating data from randomized studies and the results of large population-based studies demonstrating short-term and longer-term patient benefits support the view that HETA should be more widely used. The adoption of early treatment with HETA capitalizes on a window of opportunity for anti-inflammatory drugs to maximally impact disease pathology and heralds a sea change in clinical practice toward pro-active management and away from a philosophy routed in generating clinical benefit as a consequence of treatment failure.

Brain and Mind Centre University of Sydney Sydney Australia

Center of Neurology Lodz Poland

Department of Neurology Heinrich Heine University Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Olomouc Czech Republic

Department of Neurology University of Warmia and Mazury 30 Warszawska Ave 10 082 Olsztyn Poland

Department of Neurology Weill Neurosciences Institute UCSF San Francisco USA

Faculty of Brain Sciences University College London London UK

Zobrazit více v PubMed

McGinley M, Goldschmidt Ch, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis. A review. JAMA. 2021;325:765–779. PubMed

Comi G, Radaelli M, Soelberg P, et al. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347–1356. PubMed

Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis—success from bench to bedside. Nat Rev Neurol. 2019;15:53–58. PubMed

Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32:365–377. PubMed

Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120. PubMed

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–788. PubMed

Förster M, Graf J, Mares J, et al. Drug treatment of clinically isolated syndrome. CNS Drugs. 2019;33:659–676. PubMed

Trojano M, Iaffaldano P. Assessing long-term effectiveness of MS treatment—a matter of debate. Nat Rev Neurol. 2021;17:197–198. PubMed

Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23:1233–1240. PubMed

Iaffaldano P, Lucisano G, Butzkueven H, et al. Early treatment delays long-term disability accrual in RRMS: results from the BMSD network. Mult Scler. 2021;27:1543–1555. PubMed

Kalincik T, Diouf I, Sharmin S, et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology. 2021;96:e783–e797. PubMed PMC

Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77:1132–1140. PubMed PMC

Lublin FD, Haring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145:3147–3161. PubMed PMC

Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. Brain. 1989;112:1419–1428. PubMed

Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–1438. PubMed

Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81:907–912. PubMed

Koch M, Uyttenboogaart M, van Harten A, et al. Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler. 2008;14:799–803. PubMed

Manouchehrinia A, Zhu F, Piani-Meier D, et al. Predicting risk of secondary progression in multiple sclerosis: a nomogram. Mult Scler. 2019;25:1102–1112. PubMed

Häring DA, Kropshofer H, Kappos L, et al. Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol Neuroimmunol Neuroinflamm. 2020;7:e856. PubMed PMC

Tallantyre EC, Major PC, Atherton MJ, et al. How common is truly benign MS in a UK population? J Neurol Neurosurg Psychiatry. 2019;90:522–528. PubMed PMC

Ellenberger D, Flachenecker P, Haas J, et al. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Mult Scler Relat Disord. 2020;46:102485. PubMed

Mathey G, Pisché G, Soudant M, et al. Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course. J Neurol. 2021;268:3817–3825. PubMed

Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain. 2012;135:900–911. PubMed

Hirst C, Ingram G, Swingler R, Compston DA, Pickersgill T, Robertson NP. Change in disability in patients with multiple sclerosis:a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry. 2008;79:1137–1143. PubMed

Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278–285. PubMed

Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–193. PubMed

Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, Airas L. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Brain Commun. 2021;4:fcab301. PubMed PMC

Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab vs. interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234. PubMed

Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs. teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546–557. PubMed

Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology. 2004;62:628–631. PubMed

Rieckmann P, O'Connor P, Francis GS, et al. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf. 2004;27:745–756. PubMed

Frisullo G, Calabrese M, Tortorella C, et al. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Mult Scler. 2014;20:1265–1268. PubMed

Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014;370:1270–1271. PubMed PMC

Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–554. PubMed

Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705–713. PubMed

Zagmutt FJ, Carroll CA. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Int J Neurosci. 2015;125:798–807. PubMed

Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263:1626–1632. PubMed

Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 2022;28:7–15. PubMed PMC

Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184–191. PubMed PMC

Klotz L, Havla J, Schwab N, et al. Risk and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1–31. PubMed PMC

Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324. PubMed PMC

Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–933. PubMed

Ryerson LZ, Foley J, Kister I, Cutter G, Metzger R, Goldberg JD, et al. Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) compared with every-4-week (Q4W)dosing: updated analysis of the TOUCH® Prescribing Program Database (4419) Neurology. 2021;96:4419.

Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12:756–767. PubMed

Selmaj KW, Cohen JA, Comi G, et al. Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program. Mult Scler Relat Disord. 2021;51:102844. PubMed

Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572. PubMed

Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87:688–699. PubMed

Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134. PubMed PMC

Coles AJ, Jones J, Vermersch P, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit/risk following review of trial and post-marketing data. Mult Scler. 2022;28:842–846. PubMed PMC

Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus. teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387:704–714. PubMed

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis

MS treatment de-escalation: review and commentary

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review